Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ZNF816	rs9304742	CC + CT	adalimumab	efficacy	yes	as measured by PASI75 at 3 months.	Genotypes CC + CT is associated with increased response to adalimumab or infliximab in people with Psoriasis as compared to genotype TT.	29192552	1449155520
ZNF816	rs9304742	CC	Tumor necrosis factor alpha	efficacy	yes	Moderate-to-severe plaque psoriasis. Patients were considered responders if they achieved a 75% improvement over their baseline Psoriasis Area and Severity Index (PASI) (PASI75). PASI data was collected at 3 months, 6 months and 1 year. This variant was significantly associated with response at 3 months.	Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes CT + TT.	27670765	1448522639
ZNF816	rs9304742	CC	etanercept	efficacy	yes		Genotype CC is associated with decreased response to etanercept in people with Psoriasis as compared to genotypes CT + TT.	28470127	1448631732
ZNF816	rs9304742	CC + CT	ustekinumab	efficacy	yes	as measured by PASI75 at 4 months and adjusted for weight and FDR.	Genotypes CC + CT is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype TT.	27977334	1448594922